Research Analysts Offer Predictions for PepGen Q3 Earnings

PepGen, Inc. (NASDAQ:PEPG) – Equities researchers at Wedbush reduced their Q3 2025 EPS estimates for PepGen in a research report issued on Tuesday, September 30th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.75) per share for the quarter, down from their previous forecast of ($0.73). Wedbush has a “Outperform” rating and a $9.00 price target on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. Wedbush also issued estimates for PepGen’s Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($2.44) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.34) EPS, FY2027 earnings at ($1.23) EPS, FY2028 earnings at ($1.20) EPS and FY2029 earnings at ($0.06) EPS.

A number of other equities analysts have also recently weighed in on PEPG. HC Wainwright lifted their price target on PepGen from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Stifel Nicolaus raised their target price on shares of PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Finally, Guggenheim reissued a “buy” rating and issued a $6.00 target price on shares of PepGen in a research report on Wednesday, September 24th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.40.

PepGen Stock Up 7.9%

Shares of NASDAQ PEPG opened at $5.08 on Thursday. PepGen has a 52-week low of $0.88 and a 52-week high of $9.94. The stock has a market capitalization of $166.62 million, a price-to-earnings ratio of -1.72 and a beta of 1.92. The stock’s fifty day simple moving average is $1.85 and its 200 day simple moving average is $1.56.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.15.

Hedge Funds Weigh In On PepGen

A number of hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP lifted its stake in PepGen by 17.2% in the fourth quarter. Wellington Management Group LLP now owns 47,506 shares of the company’s stock valued at $180,000 after acquiring an additional 6,989 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of PepGen during the 1st quarter worth $25,000. Bank of America Corp DE raised its holdings in shares of PepGen by 54.7% during the 4th quarter. Bank of America Corp DE now owns 53,868 shares of the company’s stock valued at $204,000 after purchasing an additional 19,056 shares in the last quarter. Rangeley Capital LLC lifted its stake in shares of PepGen by 133.3% in the 2nd quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after purchasing an additional 20,000 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in PepGen in the first quarter worth $29,000. 58.01% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, major shareholder Science Enterprises Plc Oxford bought 200,000 shares of the business’s stock in a transaction on Tuesday, September 30th. The stock was bought at an average price of $3.20 per share, for a total transaction of $640,000.00. Following the transaction, the insider directly owned 4,955,388 shares in the company, valued at $15,857,241.60. This represents a 4.21% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 5.20% of the company’s stock.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.